<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100485</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS2108</org_study_id>
    <nct_id>NCT05100485</nct_id>
  </id_info>
  <brief_title>A Novel Algorithm to Stratify Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108): An International, Multicenter Cohort Study</brief_title>
  <official_title>ABC: A Novel Algorithm to Stratify Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108): An International, Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiyuan third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ehime University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hyogo College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zagazing University Faculty of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Liver and Biliary Sciences (ILBS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compensated advanced chronic liver disease (cACLD) commonly indicates severe fibrosis and&#xD;
      compensated cirrhosis at risk of developing clinically significant portal hypertension (CSPH)&#xD;
      and hepatic decompensation.The presence of CSPH (defined as hepatic venous pressure gradient&#xD;
      [HVPG] ≥ 10 mmHg) is the strongest predictor of hepatic decompensation. However, HVPG&#xD;
      measurement is invasive, operator dependent, and not widely available.According to the 2021&#xD;
      updated EASL Clinical Practice Guidelines,1 cACLD patients who did not meet the Baveno VI&#xD;
      criteria but had any of the two variables (LSM &gt; 20 kPa or PLT &lt; 150 × 109/L) were suggested&#xD;
      to perform screening endoscopy and HVPG measurement. However, the number of cACLD patients&#xD;
      with unfavorable Baveno VI status is huge, no detailed risk stratifications existed at this&#xD;
      timepoint. This study intended to investigate a novel algorithm to stratify the&#xD;
      decompensation risk in patients with cACLD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compensated advanced chronic liver disease (cACLD) commonly indicates severe fibrosis and&#xD;
      compensated cirrhosis at risk of developing clinically significant portal hypertension (CSPH)&#xD;
      and hepatic decompensation.The presence of CSPH (defined as hepatic venous pressure gradient&#xD;
      [HVPG] ≥ 10 mmHg) is the strongest predictor of hepatic decompensation. However, HVPG&#xD;
      measurement is invasive, operator dependent, and not widely available.According to the 2021&#xD;
      updated EASL Clinical Practice Guidelines,1 cACLD patients who did not meet the Baveno VI&#xD;
      criteria but had any of the two variables (LSM &gt; 20 kPa or PLT &lt; 150 × 109/L) were suggested&#xD;
      to perform screening endoscopy and HVPG measurement. However, the number of cACLD patients&#xD;
      with unfavorable Baveno VI status is huge, no detailed risk stratifications existed at this&#xD;
      timepoint. This study intended to investigate a novel algorithm to stratify the&#xD;
      decompensation risk in patients with cACLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 21, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of a novel algorithm for predicting liver decompensation.</measure>
    <time_frame>3 years</time_frame>
    <description>Aims to investigate the accuracy of the novel algorithm to stratify decompensation risk in patients with cACLD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The accuracy of the novel alogrithm for predicting clinically significant portal hypertension.</measure>
    <time_frame>1 years</time_frame>
    <description>HVPG cohort was used to evaluate the accuracy of the novel alogrithm for predicting clinically significant portal hypertension.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Compensated Advanced Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Training cohort was used to developement the new algorithm for predicting liver decompensation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>Validation cohort was used to test the performance of the new algorithm in predicting liver decompensation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HVPG cohort</arm_group_label>
    <description>HVPG cohort, a cross-section cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Esophagogasrtoduodendoscopy</intervention_name>
    <description>Esophagogasrtoduodendoscopy was used to detech the presence of varices.</description>
    <arm_group_label>HVPG cohort</arm_group_label>
    <arm_group_label>Training cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hepatic venous pressure gradient</intervention_name>
    <description>A method used to eveluate the portal pressure</description>
    <arm_group_label>HVPG cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an international, multicenter cohort study initialed by Chinese Portal Hypertension&#xD;
        Alliance (CHESS) and eligible patients were enrolled from China, Japan, Southern Korea,&#xD;
        Egypt, Singapore, and India.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Training and Validation cohort.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) age above or equal to 18-year-old, (2) fulfilled diagnosis of cACLD based on&#xD;
             radiological, histological features of severe fibrosis or cirrhosis according to the&#xD;
             Baveno VI consensus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) prior hepatic decompensation, (2) hepatocellular carcinoma, (3) prior liver&#xD;
             transplantation, (4) portal vein thrombosis, (5) antiplatelet or anticoagulation, (6)&#xD;
             without screening endoscopy within six months of transient elastography, (7) alcoholic&#xD;
             cirrhosis with significant ongoing alcohol intake, (8) presence of gastric varix, (9)&#xD;
             incomplete follow-up data.&#xD;
&#xD;
        HVPG cohort.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) age above or equal to 18-year-old, (2) fulfilled diagnosis of cACLD based on&#xD;
             radiological, histological features of severe fibrosis or cirrhosis according to the&#xD;
             Baveno VI consensus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) prior hepatic decompensation, (2) hepatocellular carcinoma, (3) prior liver&#xD;
             transplantation, (4) portal vein thrombosis, (5) antiplatelet or anticoagulation, (6)&#xD;
             without screening endoscopy within six months of transient elastography, (7) alcoholic&#xD;
             cirrhosis with significant ongoing alcohol intake, (8) presence of gastric varix, (9)&#xD;
             non-sinusoidal portal hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Qi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lanzhou University First Affiliated Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qing Xie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong university affiliated Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Second People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Jun Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masashi Hirooka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ehime University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hirayuki Enomoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hyogo College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Hyung Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea UniversityAnsan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amr Shaaban Hanafy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zagazig University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third People's Hospital of Taiyuan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiv Sarin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences (ILBS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi, MD</last_name>
    <phone>+8618588602600</phone>
    <phone_ext>+8618588602600</phone_ext>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuan Liu, MD</last_name>
    <phone>+8615626415443</phone>
    <phone_ext>+8615626415443</phone_ext>
    <email>845424585@qq.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):708-719. doi: 10.1016/S2468-1253(18)30232-2. Review.</citation>
    <PMID>30215362</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22. Erratum in: Lancet. 2019 Jun 22;393(10190):2492.</citation>
    <PMID>30910320</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative:; Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21.</citation>
    <PMID>34166721</PMID>
  </reference>
  <reference>
    <citation>Albilllos A, Garcia-Tsao G. Classification of cirrhosis: the clinical use of HVPG measurements. Dis Markers. 2011;31(3):121-8. doi: 10.3233/DMA-2011-0834. Review.</citation>
    <PMID>22045397</PMID>
  </reference>
  <reference>
    <citation>Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007 Aug;133(2):481-8. Epub 2007 May 21.</citation>
    <PMID>17681169</PMID>
  </reference>
  <reference>
    <citation>Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82. doi: 10.1038/nrgastro.2009.149. Epub 2009 Sep 1. Review.</citation>
    <PMID>19724251</PMID>
  </reference>
  <reference>
    <citation>Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.</citation>
    <PMID>30768988</PMID>
  </reference>
  <reference>
    <citation>Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, Procopet B, Bosch J, Genesca J, Berzigotti A; Anticipate Investigators. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The &quot;Anticipate&quot; study. Hepatology. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. Epub 2016 Oct 27. Erratum in: Hepatology. 2017 Jul;66(1):304-305.</citation>
    <PMID>27639071</PMID>
  </reference>
  <reference>
    <citation>Chen RC, Cai YJ, Wu JM, Wang XD, Song M, Wang YQ, Zheng MH, Chen YP, Lin Z, Shi KQ. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepat. 2017 Mar;24(3):238-245. doi: 10.1111/jvh.12638. Epub 2016 Nov 14.</citation>
    <PMID>27862671</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>liver stiffness</keyword>
  <keyword>platelets</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>varices</keyword>
  <keyword>compensated advanced chronic liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

